Skip to main content

Table 1 Demographic, laboratory and clinical variables in NAFLD subjects and controls

From: Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study

Variable NAFLD subjects (n = 80) Controls (n = 83) p
Age (years) (mean ± SD) 53.7 ± 12.9 51.7 ± 17.2 0.401
Weight (kg) (mean ± SD) 78.9 ± 17.7 71.3 ± 13.4 0.002
BMI (kg/m2) (mean ± SD) 28.7 ± 5.6 25.3 ± 3.8 0.005
SBP (mm/Hg) (mean ± SD) 121.7 ± 13.7 122.7 ± 16.3 0.655
DBP (mm/Hg) (mean ± SD) 72.7 ± 9.5 75.4 ± 12.7 0.127
Hypertension (n/%) 28 (35.0) 13 (15.7) 0.006
Diabetes (n/%) 31 (38.8) 7 (8.4) 0.005
Dyslipidaemia (n/%) 15 (18.8) 14 (16.9) 0.839
Previous cardiovascular diseases 3 (3.75) 0 0.341
Previous cerebrovascular events 0 0 0.417
RHI (mean ± SD) 1.85 ± 0.5 2.20 ± 0.6 0.005
Aix (%) (mean ± SD) 144.3 ± 27.2 131.4 ± 31.4 0.006
PWV (mt/s) (mean ± SD) 10.46 ± 2.1 9.61 ± 2.30 0.015
MMSE (mean ± SD) 26.9 ± 1.6 28.0 ± 1.4 0.005
Liver stiffness, kPa 9.37 ± 7.7 4.5 ± 0.4 0.005
NASH patients (n/%) 52   
Histology (%) 52 (65)   
Kleiner steatosis grade 0–3 (mean/SD)
 1 (n/%) 36 (45)   
 2 (n/%) 22 (27.5)   
 3 (n/%) 22 (27.5)   
Lobular inflammation grade 0–3 (mean/SD)
 0 (n/%) 2 (2.5)   
 1 (n/%) 45 (56.3)   
 2 (n/%) 31 (38.8)   
 3 (n/%) 2 (2.5)   
Hepatocellular ballooning 0–2 (mean/SD)
 0 (n/%) 23 (28.7)   
 1 (n/%) 35 (43.8)   
 2 (n/%) 22 (27.5)   
Stage of fibrosis (0–4) (mean/SD)
 0 (n/%) 18 (22.5)   
 1 (n/%) 25 (31.3)   
 2 (n/%) 14 (17.5)   
 3 (n/%) 17 (21.3)   
 4 (n/%) 6 (7.5)   
  1. Liver stiffness: measured by transient elastography (TE) (fibroscan)
  2. Significant p values are indicated in Italics
  3. SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, Aix: augmentation index, PWV pulse wave velocity, RHI reactive hyperemia index, MMSE mini-mental state examination, kPa kilopascal